West Pharmaceutical Services Inc. (NYSE:WST) Stake Reduced by Neuberger Berman Group LLC

Neuberger Berman Group LLC decreased its stake in West Pharmaceutical Services Inc. (NYSE:WST) by 2.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,612,559 shares of the medical instruments supplier’s stock after selling 61,715 shares during the period. Neuberger Berman Group LLC owned 3.56% of West Pharmaceutical Services worth $287,904,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of WST. BlackRock Inc. raised its position in West Pharmaceutical Services by 2.5% during the 1st quarter. BlackRock Inc. now owns 7,111,791 shares of the medical instruments supplier’s stock worth $783,720,000 after buying an additional 172,298 shares during the last quarter. Vanguard Group Inc raised its position in West Pharmaceutical Services by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 7,067,729 shares of the medical instruments supplier’s stock worth $872,652,000 after buying an additional 139,098 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in West Pharmaceutical Services by 9,703.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,836,204 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 2,807,272 shares during the last quarter. WCM Investment Management LLC raised its position in West Pharmaceutical Services by 1.2% during the 1st quarter. WCM Investment Management LLC now owns 1,122,116 shares of the medical instruments supplier’s stock worth $123,658,000 after buying an additional 13,448 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in shares of West Pharmaceutical Services by 0.5% in the 1st quarter. Artisan Partners Limited Partnership now owns 1,111,465 shares of the medical instruments supplier’s stock valued at $122,483,000 after purchasing an additional 5,052 shares in the last quarter. Institutional investors and hedge funds own 91.90% of the company’s stock.

WST has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Friday, April 19th. William Blair initiated coverage on shares of West Pharmaceutical Services in a report on Tuesday, April 23rd. They issued an “outperform” rating and a $112.16 price target for the company. Finally, Jefferies Financial Group downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 price target for the company. in a report on Wednesday, May 1st.

In other West Pharmaceutical Services news, VP Daniel Malone sold 4,458 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $123.03, for a total transaction of $548,467.74. Following the transaction, the vice president now directly owns 33,478 shares of the company’s stock, valued at $4,118,798.34. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.70% of the company’s stock.

Shares of West Pharmaceutical Services stock traded up $1.57 during mid-day trading on Friday, hitting $125.15. 1,071,719 shares of the stock were exchanged, compared to its average volume of 225,640. The stock has a 50-day moving average of $118.88. The company has a quick ratio of 2.13, a current ratio of 2.88 and a debt-to-equity ratio of 0.19. West Pharmaceutical Services Inc. has a twelve month low of $91.75 and a twelve month high of $125.86. The company has a market cap of $9.08 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 3.75 and a beta of 1.30.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 25th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.08. West Pharmaceutical Services had a net margin of 12.53% and a return on equity of 16.38%. The business had revenue of $443.50 million for the quarter, compared to analysts’ expectations of $431.00 million. During the same period last year, the company earned $0.62 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. As a group, equities research analysts expect that West Pharmaceutical Services Inc. will post 2.88 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 24th will be given a dividend of $0.15 per share. The ex-dividend date is Tuesday, July 23rd. This represents a $0.60 dividend on an annualized basis and a yield of 0.48%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 21.35%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Further Reading: Correction

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.